Final answer:
Clients taking an anticoagulant, like enoxaparin, may develop bleeding due to the medication's effect on blood clotting factors. The balance of blood coagulation is affected, therefore increasing the risk of excessive bleeding despite the benefits in preventing thrombosis.
Step-by-step explanation:
Clients taking an anticoagulant, such as enoxaparin, might develop bleeding. Anticoagulants are medications that help prevent the formation of blood clots by inhibiting certain clotting factors in the blood. While these drugs, including others like warfarin (Coumadin), rivaroxaban (Xarelto), apixaban (Eliquis), and various forms of heparin, are crucial in treating and preventing thrombosis and deep vein thrombosis (DVT), they also carry a risk of excessive bleeding. This is because they affect the delicate balance of coagulation, reducing the body's ability to clot blood which is a necessary process to stop bleeding. Pharmacogenomics can be particularly useful for tailoring anticoagulant dosages to individual patients, as liver function and genetic factors can influence how a person responds to these medications, impacting their risk for both thrombosis and bleeding.